{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:43:40Z","timestamp":1788403420310,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"48","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Academic Research Organization"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\u2003<\/jats:title>\n                    <jats:p>Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin\u2013angiotensin\u2013aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium\u2012glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results\u2003<\/jats:title>\n                    <jats:p>The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to either investigator-reported hyperkalaemia or the initiation of potassium binders. We also analysed effects on central laboratory-determined hyper- and hypokalaemia (serum potassium \u22656.0 and &amp;lt;3.5\u2009mmol\/L, respectively) and change in serum potassium. At baseline, the mean serum potassium in canagliflozin and placebo arms was 4.5\u2009mmol\/L; 4395 (99.9%) participants were receiving renin\u2013angiotensin system blockade. The incidence of investigator-reported hyperkalaemia or initiation of potassium binders was lower with canagliflozin than with placebo [occurring in 32.7 vs. 41.9 participants per 1000 patient-years; hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.64\u20130.95, P\u2009=\u20090.014]. Canagliflozin similarly reduced the incidence of laboratory-determined hyperkalaemia (HR 0.77, 95% CI 0.61\u20130.98, P\u2009=\u20090.031), with no effect on the risk of hypokalaemia (HR 0.92, 95% CI 0.71\u20131.20, P\u2009=\u20090.53). The mean serum potassium over time with canagliflozin was similar to that of placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion\u2003<\/jats:title>\n                    <jats:p>Among patients treated with renin\u2013angiotensin\u2013aldosterone system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab497","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T15:11:37Z","timestamp":1626361897000},"page":"4891-4901","source":"Crossref","is-referenced-by-count":114,"title":["Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L","family":"Neuen","sequence":"first","affiliation":[{"name":"Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney , Sydney, NSW 2042, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-5229","authenticated-orcid":false,"given":"Megumi","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Laboratory Medicine, Kanazawa University , Kanazawa, Ishikawa 920-1192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4257-7620","authenticated-orcid":false,"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of New South Wales , Sydney, NSW 2052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine and VA Medical Center, Indianapolis , IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-9913","authenticated-orcid":false,"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[{"name":"Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney , Sydney, NSW 2042, Australia"},{"name":"Department of Cardiology, Royal Prince Alfred Hospital , Sydney, NSW 2050, Australia"},{"name":"Sydney Medical School, University of Sydney , Sydney, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago Medicine , Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Cannon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital , Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-3583","authenticated-orcid":false,"given":"David M","family":"Charytan","sequence":"additional","affiliation":[{"name":"Nephrology Division, New York University Langone Medical Center, New York University School of Medicine , New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Edwards","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1134-9051","authenticated-orcid":false,"given":"Jose L","family":"G\u00f3rriz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Cl\u00ednico Universitario, University of Valencia , Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0160-2375","authenticated-orcid":false,"given":"Meg J","family":"Jardine","sequence":"additional","affiliation":[{"name":"Concord Repatriation General Hospital , Sydney, NSW 2139, Australia"},{"name":"NHMRC Clinical Trials Centre, University of Sydney , Sydney, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of British Columbia , Vancouver, BC V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-7465","authenticated-orcid":false,"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[{"name":"Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney , Sydney, NSW 2042, Australia"},{"name":"The Charles Perkins Centre, University of Sydney , Sydney, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8532-0182","authenticated-orcid":false,"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, Nephrology and Dialysis Unit, University Vanvitelli , Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-6495","authenticated-orcid":false,"given":"Carol","family":"Pollock","sequence":"additional","affiliation":[{"name":"Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital , St Leonards, NSW 2064, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-4979","authenticated-orcid":false,"given":"Norman","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC , Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-3478","authenticated-orcid":false,"given":"David C","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, UCL Medical School , London WC1E 6DE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford , CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen , PO Box 30001 , 9700 AD Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"2022102515342720000_ehab497-B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.kisu.2016.01.002","article-title":"Epidemiology of hyperkalemia: an update","volume":"6","author":"Kovesdy","year":"2016","journal-title":"Kidney Int Suppl"},{"key":"2022102515342720000_ehab497-B2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.12990820","article-title":"Ambulatory treatments for RAAS inhibitor\u2013related hyperkalemia and the 1-year risk of recurrence","volume":"16","author":"Hundemer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102515342720000_ehab497-B3","doi-asserted-by":"crossref","first-page":"e0213192","DOI":"10.1371\/journal.pone.0213192","article-title":"Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study","volume":"14","author":"Jun","year":"2019","journal-title":"PLoS One"},{"key":"2022102515342720000_ehab497-B4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"2022102515342720000_ehab497-B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"2022102515342720000_ehab497-B6","doi-asserted-by":"crossref","first-page":"e005428","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin\u2013angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) Project","volume":"6","author":"Bandak","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022102515342720000_ehab497-B7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022102515342720000_ehab497-B8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102515342720000_ehab497-B9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102515342720000_ehab497-B10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022102515342720000_ehab497-B11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2022102515342720000_ehab497-B12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin\u2013angiotensin\u2013aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022102515342720000_ehab497-B13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2022102515342720000_ehab497-B14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/ckj\/sfaa133","article-title":"Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program","volume":"14","author":"Weir","year":"2021","journal-title":"Clin Kidney J"},{"key":"2022102515342720000_ehab497-B15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102515342720000_ehab497-B16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"2022102515342720000_ehab497-B17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2022102515342720000_ehab497-B18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11154-016-9384-x","article-title":"Updates in hyperkalemia: outcomes and therapeutic strategies","volume":"18","author":"Kovesdy","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"2022102515342720000_ehab497-B19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"2022102515342720000_ehab497-B20","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS Program","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"2022102515342720000_ehab497-B21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102515342720000_ehab497-B22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2022102515342720000_ehab497-B23","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","article-title":"Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease","volume":"94","author":"Qiao","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2022102515342720000_ehab497-B24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022102515342720000_ehab497-B25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2022102515342720000_ehab497-B26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2022102515342720000_ehab497-B27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"key":"2022102515342720000_ehab497-B28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1681\/ASN.2008020166","article-title":"Mechanisms in hyperkalemic renal tubular acidosis","volume":"20","author":"Karet","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022102515342720000_ehab497-B29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102515342720000_ehab497-B30","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"2022102515342720000_ehab497-B31","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/48\/4891\/46628083\/ehab497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/48\/4891\/46628083\/ehab497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:54:33Z","timestamp":1666706073000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/48\/4891\/6356221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":31,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2021,8,23]]},"published-print":{"date-parts":[[2021,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab497","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,21]]},"published":{"date-parts":[[2021,8,23]]}}}